Characterization of an Antibacterial Agent Targeting Ferrous Iron Transport Protein FeoB against Staphylococcus aureus and Gram-Positive Bacteria

The emergence of multidrug-resistant Staphylococcus aureus strains has become a serious clinical problem. Iron is absolutely required for the bacterial growth, virulence associated with colonization, and survival from the host immune system. The FeoB protein is a major iron permease in bacterial ferrous iron transport systems (Feo) that has been shown to play a crucial role in virulence of some pathogenic bacteria. However, FeoB is still uncharacterized in Gram-positive pathogens, and its effects on S. aureus pathogenesis are unknown. In this study, we identified a novel inhibitor, GW3965 center dot HCl, that targets FeoB in S. aureus. The molecule effectively inhibited FeoB in vitro enzyme activity, bacterial growth, and virulence factor expression. Genome-editing and metabolomic analyses revealed that GW3965 center dot HCl inhibited FeoB function and affected the associated mechanisms with reduced iron availability in S. aureus. Gentamicin resistance and Caenorhabditis elegans infection assays further demonstrated the power of GW3965 center dot HCl as a safe and efficient antibacterial agent. In addition to S. aureus, GW3965 center dot HCl also presented its effectiveness on inhibition of the FeoB activity and growth of Gram-positive bacteria. This novel inhibitor will provide new insight for developing a next-generation antibacterial therapy.

Automated summary

The study identified a novel inhibitor, GW3965·HCl, targeting FeoB in Staphylococcus aureus, which effectively inhibited bacterial growth and virulence factor expression, demonstrating promising antibacterial activity in both in vitro and in vivo assays. Additionally, GW3965·HCl also showed effectiveness in inhibiting FeoB activity and growth of Gram-positive bacteria, suggesting potential for developing next-generation antibacterial therapies.